Proteins such as Jab1 and TRX, which are involved in cell growth, can be activated by the higher levels of ROS produced by the FLT3 mutation, suggesting that ROS/Jab1/TRX could be a therapeutic target in AML [288]. The gene discussed is FLT3; the disease is acute myeloid leukemia.